ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

6,386Medicare Part D Prescriptions Filled, Including Refills

Rank: 243 out of 625

$598K Total Retail Price of All Prescriptions

Rank: 135 out of 625

258 Patients Receiving at Least One Drug in Part D
41%Patients 65 Years and Older
93% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in South Carolina
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

5% of this provider’s 258 patients filled at least one prescription for a schedule three drug, compared to an average of 12%.

Risky Drugs to Seniors

3% of this provider’s 3,004 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

27% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$94 was the average price of a prescription from this provider, compared to $62 among peers.

Prescriptions per Patient

25 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in South Carolina
AMLODIPINE BESYLATE 383 241 1 1
PRAVASTATIN SODIUM 259 150 2 8
LISINOPRIL-HYDROCHLOROTHIAZIDE 246 127 3 27
RANITIDINE HCL 215 146 4 25
TRAMADOL HCL 200 98 5 16
METFORMIN HCL 190 87 6 10
HYDROCHLOROTHIAZIDE 188 116 7 12
SIMVASTATIN 147 50 8 2
OMEPRAZOLE 142 71 9 6
LISINOPRIL 140 64 10 5
DIOVAN HCT 116 48 11 52
GLIPIZIDE 112 41 12 56
METOPROLOL TARTRATE 110 45 13 11
CYCLOBENZAPRINE HCL 110 24 R 13 65
NAPROXEN 103 37 15 104
CLONIDINE HCL 90 59 16 50
GABAPENTIN 88 18 17 14
AMLODIPINE BESYLATE-BENAZEPRIL 88 52 17 48
NEXIUM 87 17 19 21
VENTOLIN HFA 85 43 20 93
CARVEDILOL 84 54 21 23
LEVOTHYROXINE SODIUM 83 35 22 3
PROAIR HFA 80 32 23 57
FUROSEMIDE 80 40 23 7
LANTUS 79 26 25 54
TRAZODONE HCL 78 37 26 51
METFORMIN HCL ER 77 27 27 41
TRUVADA 76 25 28 263
CRESTOR 72 48 29 17
ATORVASTATIN CALCIUM 68 48 30 9
INSULIN SYRINGE 68 11 30 77
ATRIPLA 58 23 32 249
METOPROLOL SUCCINATE 56 54 33 15
ALLOPURINOL 55 42 34 29
LANTUS SOLOSTAR 55 29 34 85
LEVETIRACETAM 53 12 36 98
POTASSIUM CHLORIDE 52 23 37 19
PAROXETINE HCL 52 18 37 76
EXFORGE 50 40 39 152
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 10, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.